Home Newsfeeds Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.

Fulcrum Therapeutics, AMTD Digital, Hasbro And Other Big Stocks Moving Higher On Tuesday

By Lisa Levin

August 22, 10:29 AM

U.S. stocks traded mixed, with the Dow Jones falling around 100 points on Monday. Here are some big stocks recording gains in today’s session.

ASLE

Movers
News

What’s Going On With Microsoft Stock Monday?

By Adam Eckert

November 20, 10:07 AM

Microsoft Corp (NASDAQ: MSFT) shares are trading higher Monday after CEO Satya Nadella announced that OpenAI's Sam Altman and Greg Brockman

MSFT

FTX, Bahamas Regulator Fight Over Control Of Bankruptcy Proceedings: WSJ

By Mehab Qureshi

November 17, 1:33 AM

Securities regulators in the Bahamas are reportedly seeking to control FTX (CRYPTO: FTT) bankruptcy proceedings, challenging the company’s Chapter 11 filing in the U.S.

$FTT

Cowen & Co. Maintains Outperform on Crown Castle, Raises Price Target to $152

By Benzinga Newsdesk

January 27, 11:09 AM

Cowen & Co. analyst Gregory Williams maintains Crown Castle (NYSE:CCI) with a Outperform and raises the price target from $149 to $152.

CCI

Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Related Posts

Fulcrum Therapeutics, AMTD Digital, Hasbro And Other Big Stocks Moving Higher On Tuesday

What’s Going On With Microsoft Stock Monday?

FTX, Bahamas Regulator Fight Over Control Of Bankruptcy Proceedings: WSJ

Cowen & Co. Maintains Outperform on Crown Castle, Raises Price Target to $152